|
1
|
Arndt CA, Rose PS, Folpe AL and Laack NN:
Common musculoskeletal tumors of childhood and adolescence. Mayo
Clin Proc. 87:475–487. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ta HT, Dass CR, Choong PF and Dunstan DE:
Osteosarcoma treatment: State of the art. Cancer Metastasis Rev.
28:247–263. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kempf-Bielack B, Bielack SS, Jurgens H,
Branscheid D, Berdel WE, Exner GU, Göbel U, Helmke K, Jundt G,
Kabisch H, et al: Osteosarcoma relapse after combined modality
therapy: An analysis of unselected patients in the Cooperative
Osteosarcoma Study Group (COSS). J Clin Oncol. 23:559–568. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thompson LD: Osteosarcoma. Ear, Nose
Throat J. 92:288–290. 2013.
|
|
5
|
Chang Z, Huo L, Li K, Wu Y and Hu Z:
Blocked autophagy by miR-101 enhances osteosarcoma cell
chemosensitivity in vitro. ScientificWorldJournal.
2014:e7947562014. View Article : Google Scholar
|
|
6
|
Zhou Y, Huang Z, Wu S, Zang X, Liu M and
Shi J: miR-33a is up-regulated in chemoresistant osteosarcoma and
promotes osteosarcoma cell resistance to cisplatin by
down-regulating TWIST. J Exp Clin Cancer Res. 33:122014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang Y and Lee CG: MicroRNA and
cancer-focus on apoptosis. J Cell Mol Med. 13:12–23. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Iorio MV and Croce CM: MicroRNAs in
cancer: Small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lu C, Xie Z and Peng Q: MiRNA-107 enhances
chemosensitivity to paclitaxel by targeting antiapoptotic factor
Bcl-w in non small cell lung cancer. Am J Cancer Res. 7:1863–1873.
2017.PubMed/NCBI
|
|
11
|
Zhang J, Qiu W, Xu S, Yu Q, Liu C, Wang Y,
Lu A, Zhang J and Lu X: 1MicroRNA-625 inhibits the
proliferation and increases the chemosensitivity of glioma by
directly targeting AKT2. Am J Cancer Res. 7:1835–1849.
2017.PubMed/NCBI
|
|
12
|
Li Y, Luo T, Wang L, Wu J and Guo S:
MicroRNA-19a-3p enhances the proliferation and insulin secretion,
while it inhibits the apoptosis of pancreatic β cells via the
inhibition of SOCS3. Int J Mol Med. 38:1515–1524. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Soria JC, Lee HY, Lee JI, Wang L, Issa JP,
Kemp BL, Liu DD, Kurie JM, Mao L and Khuri FR: Lack of PTEN
expression in non-small cell lung cancer could be related to
promoter methylation. Clin Cancer Res. 8:1178–1184. 2002.PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shen J, Niu W and Zhang H, Jun M and Zhang
H: Downregulation of MicroRNA-147 Inhibits Cell Proliferation and
Increases the Chemosensitivity of Gastric Cancer Cells to
5-Fluorouracil by Directly Targeting PTEN. Oncol Res. doi:
10.3727/096504017X15061902533715. 2017.
|
|
16
|
Bielack SS, Kempf-Bielack B, Delling G,
Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M,
Winkelmann W, et al: Prognostic factors in high-grade osteosarcoma
of the extremities or trunk: An analysis of 1,702 patients treated
on neoadjuvant cooperative osteosarcoma study group protocols. J
Clin Oncol. 20:776–790. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lei W, Yan C, Ya J, Yong D, Yujun B and
Kai L: MiR-199a-3p affects the multi-chemoresistance of
osteosarcoma through targeting AK4. BMC cancer. 18:6312018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xie B, Li Y, Zhao R, Xu Y, Wu Y, Wang J,
Xia D, Han W and Chen D: Identification of key genes and miRNAs in
osteosarcoma patients with chemoresistance by bioinformatics
analysis. Biomed Res Int. 2018:47610642018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang SN, Luo S, Liu C, Piao Z, Gou W, Wang
Y, Guan W, Li Q, Zou H, Yang ZZ, et al: miR-491 inhibits
osteosarcoma lung metastasis and chemoresistance by targeting
alphaB-crystallin. Mol Ther. 25:2140–2149. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rajabpour A, Afgar A, Mahmoodzadeh H,
Radfar JE, Rajaei F and Teimoori-Toolabi L: MiR-608 regulating the
expression of ribonucleotide reductase M1 and cytidine deaminase is
repressed through induced gemcitabine chemoresistance in pancreatic
cancer cells. Cancer Chemother Pharmacol. 80:765–775. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zou M, Wang F, Gao R, Wu J, Ou Y, Chen X,
Wang T, Zhou X, Zhu W, Li P, et al: Autophagy inhibition of
hsa-miR-19a-3p/19b-3p by targeting TGF-β R II during TGF-β1-induced
fibrogenesis in human cardiac fibroblasts. Sci Rep. 6:247472016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu M, Huang Z, Zhu D, Zhou X, Shan X, Qi
LW, Wu L, Cheng W, Zhu J, Zhang L, et al: A panel of microRNA
signature in serum for colorectal cancer diagnosis. Oncotarget.
8:17081–17091. 2017.PubMed/NCBI
|
|
24
|
Lotan TL, Heumann A, Rico SD, Hicks J,
Lecksell K, Koop C, Sauter G, Schlomm T and Simon R: PTEN loss
detection in prostate cancer: Comparison of PTEN
immunohistochemistry and PTEN FISH in a large retrospective
prostatectomy cohort. Oncotarget. 8:65566–65576. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ma J, Guo X, Zhang J, Wu D, Hu X, Li J,
Lan Q, Liu Y and Dong W: PTEN gene induces cell invasion and
migration via regulating AKT/GSK-3β/β-Catenin signaling pathway in
human gastric cancer. Dig Dis Sci. 62:3415–3425. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu F, Zhao X, Qian Y, Zhang J, Zhang Y
and Yin R: MiR-206 inhibits Head and neck squamous cell carcinoma
cell progression by targeting HDAC6 via PTEN/AKT/mTOR pathway.
Biomed Pharmacother. 96:229–237. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ma Y, Zhang P, Gao Y, Fan H, Zhang M and
Wu J: Evaluation of AKT phosphorylation and PTEN loss and their
correlation with the resistance of rituximab in DLBCL. Int J Clin
Exp Pathol. 8:14875–14884. 2015.PubMed/NCBI
|
|
28
|
Wei H, Cui R, Bahr J, Bahr J, Zanesi N,
Luo Z, Meng W, Liang G and and Croce CM: miR-130a deregulates PTEN
and stimulates tumor growth. Cancer Res. 77:6168–6178. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yu X, Chen Y, Tian R, Li J, Li H, Lv T and
Yao Q: miRNA-21 enhances chemoresistance to cisplatin in epithelial
ovarian cancer by negatively regulating PTEN. Oncol Lett.
14:1807–1810. 2017. View Article : Google Scholar : PubMed/NCBI
|
